Sangamo Therapeutics Inc (SGMO) concluded trading on Thursday at a closing price of $0.96, with 3.63 million shares of worth about $3.49 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 17.94% during that period and on February 27, 2025 the price saw a loss of about -2.24%. Currently the company’s common shares owned by public are about 208.62M shares, out of which, 200.01M shares are available for trading.
Stock saw a price change of -14.54% in past 5 days and over the past one month there was a price change of -15.30%. Year-to-date (YTD), SGMO shares are showing a performance of -6.17% which decreased to -14.54% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.30 but also hit the highest price of $3.18 during that period. The average intraday trading volume for Sangamo Therapeutics Inc shares is 6.50 million. The stock is currently trading -15.50% below its 20-day simple moving average (SMA20), while that difference is down -33.24% for SMA50 and it goes to -15.28% lower than SMA200.
Sangamo Therapeutics Inc (NASDAQ: SGMO) currently have 208.62M outstanding shares and institutions hold larger chunk of about 29.74% of that.
The stock has a current market capitalization of $199.70M and its 3Y-monthly beta is at 1.51. It has posted earnings per share of -$0.74 in the same period. It has Quick Ratio of 1.35 while making debt-to-equity ratio of 0.71. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for SGMO, volatility over the week remained 9.44% while standing at 8.39% over the month.
Stock’s fiscal year EPS is expected to rise by 68.13% while it is estimated to increase by 51.24% in next year. EPS is likely to grow at an annualized rate of 39.84% for next 5-years, compared to annual growth of -15.96% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Truist on December 13, 2024 offering a Buy rating for the stock and assigned a target price of $7 to it. Coverage by H.C. Wainwright stated Sangamo Therapeutics Inc (SGMO) stock as a Buy in their note to investors on December 10, 2024, suggesting a price target of $10 for the stock. On November 03, 2023, RBC Capital Mkts Downgrade their recommendations, while on April 28, 2023, BofA Securities Downgrade their ratings for the stock with a price target of $1.50. Stock get an Outperform rating from Wedbush on February 27, 2023.
